Market Place
Sourcing Support
Athersys files for Chapter 11 bankruptcy, sells everything to partner Healios
09 Jan 2024 //
ENDPTS
Athersys files for bankruptcy, sells assets to Healios
09 Jan 2024 //
FIERCE BIOTECH
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
16 Nov 2023 //
BUSINESSWIRE
Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement
16 Oct 2023 //
BUSINESSWIRE
Athersys Reports Analysis Results of MASTERS-2 Clinical Study with MultiStem
10 Oct 2023 //
BUSINESSWIRE
Athersys nears bankruptcy as cell therapy fails interim analysis
10 Oct 2023 //
FIERCE BIOTECH
Athersys Licenses its Animal Health Assets to Ardent Animal Health
03 Oct 2023 //
BUSINESSWIRE
Athersys Director Jane Wasman Appointed Board Chair
02 Oct 2023 //
BUSINESSWIRE
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
17 Aug 2023 //
BUSINESSWIRE
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
16 Aug 2023 //
BUSINESSWIRE
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
11 Aug 2023 //
BUSINESSWIRE
Athersys to Host Business Update Conference Call on August 9th
31 Jul 2023 //
BUSINESSWIRE
Patient Enrollment Begins in Third & Final Cohort of the Phase 2 MATRICS-1 Study
01 Jun 2023 //
BUSINESSWIRE
Athersys Restructures Debt with Supplier
23 May 2023 //
BUSINESSWIRE
Athersys Reports First Quarter 2023 Financial Results and Business Highlights
18 May 2023 //
BUSINESSWIRE
Athersys to Participate in Three Upcoming Conferences
08 May 2023 //
BUSINESSWIRE
Athersys to Participate in The Cellular Therapies & Transfusion Medicine Trauma
01 May 2023 //
BUSINESSWIRE
Athersys to Participate in The American Society for Neural Therapy
21 Apr 2023 //
BUSINESSWIRE
Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering
19 Apr 2023 //
BUSINESSWIRE
Athersys, Inc. Announces $3.7 M Registered Direct Offerin
18 Apr 2023 //
BUSINESSWIRE
Athersys to Host Business Update Conference Call on April 20th
10 Apr 2023 //
BUSINESSWIRE
Athersys Reports 4Q & 2022 Financial Results and Business Highlights
31 Mar 2023 //
BUSINESSWIRE
Athersys Announces Successful Type B Meeting with the FDA
22 Mar 2023 //
BUSINESSWIRE
Athersys Expands IP Protection with First New Patent for SIFU® Technology
28 Feb 2023 //
BUSINESSWIRE
Athersys Granted Type B Meeting with FDA for MASTERS-2 Trial Protocol Discussion
14 Feb 2023 //
BUSINESSWIRE
Athersys to Host Business Update Conference Call on February 14th
02 Feb 2023 //
BUSINESSWIRE
Athersys to Participate in Stroke Conference and BioProcess International
30 Jan 2023 //
BUSINESSWIRE
Athersys to Participate in Advanced Therapies Week Summit Europe in January
11 Jan 2023 //
BUSINESSWIRE
Athersys Provides MultiStem Clinical Update
09 Jan 2023 //
BUSINESSWIRE
Athersys Reports Third Quarter 2022 Financial Results
15 Nov 2022 //
BUSINESSWIRE
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells
11 Nov 2022 //
BUSINESSWIRE
Athersys Reschedules Third Quarter Conference Call to November 15
10 Nov 2022 //
BUSINESSWIRE
Athersys, Inc. Announces Closing of $5.5 Million Confidentially MPO
10 Nov 2022 //
BUSINESSWIRE
Athersys, Inc. Announces Pricing of $5.5 M Public Offering
09 Nov 2022 //
BUSINESSWIRE
Athersys, Inc. Announces Proposed Public Offering
07 Nov 2022 //
BUSINESSWIRE
Athersys to Host Third Quarter Financial Results Call
25 Oct 2022 //
BUSINESSWIRE
Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference
04 Oct 2022 //
BUSINESSWIRE
Athersys to Host Business Update Conference Call on October 6th
30 Sep 2022 //
BUSINESSWIRE
Athersys Amends Securities Purchase Agreement with Registered Direct Offering
23 Sep 2022 //
BUSINESSWIRE
Athersys Announces 1-for-25 Reverse Stock Split
25 Aug 2022 //
BUSINESSWIRE
Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
17 Aug 2022 //
BUSINESSWIRE
Athersys, Inc. Announces $12 Million Registered Direct Offering
15 Aug 2022 //
BUSINESSWIRE
Athersys Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Athersys to Host Second Quarter Financial Results Call
26 Jul 2022 //
BUSINESSWIRE
Athersys and Aspire Capital Fund Terminate Relationship
08 Jul 2022 //
BUSINESSWIRE
Athersys Announces Board of Directors Slate for 2022 Annual Meeting
21 Jun 2022 //
BUSINESSWIRE
Athersys Postpones Annual Meeting of Stockholders
09 Jun 2022 //
BUSINESSWIRE
Prettying itself up for partners, Athersys lays off 70% of staff
04 Jun 2022 //
FIERCEBIOTECH
Athersys Announces Restructuring and Management Changes
02 Jun 2022 //
BUSINESSWIRE
Athersys stock plunges 60% after stroke stem cell therapy miss
21 May 2022 //
BIOSPACE
Athersys to Participate in the H.C. Wainwright Global Investment Conference
13 May 2022 //
BUSINESSWIRE
Athersys Reports First Quarter 2022 Results
06 May 2022 //
BUSINESSWIRE
Athersys to Announce First Quarter Financial Results on May 6
29 Apr 2022 //
BUSINESSWIRE
HEALIOS K.K., Provides Updates on MultiStem Clinical Programs in Japan
04 Apr 2022 //
BUSINESSWIRE
Athersys Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
BUSINESSWIRE
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17 Feb 2022 //
BUSINESSWIRE
Athersys to Host Year-End 2021 Financial Results Call
15 Feb 2022 //
BUSINESSWIRE
Athersys Appoints Daniel A. Camardo, to Chief Executive Officer
20 Jan 2022 //
BUSINESSWIRE
Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
15 Nov 2021 //
BUSINESSWIRE
HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment
10 Aug 2021 //
BUSINESSWIRE
